Market Growth of COPD

Organizing committee invites all participants from all over the world to attend “10th International Conference on COPD and Lungs’’ during May 25-26, 2020 in Kyoto, Japan.

COPD and Lungs is a global overview with the Theme: : “Innovative Study on COPD and clinical Research Issues” is designed for professionals at all levels and career phases of the Researchers, Doctors, Pharmaceuticals  and Senior scientists, who want to improve their understanding of what will drive and shape the future of the market. This will include senior executives, sales and marketing personnel, strategic planners, who will be benefit from a broad overview of the Researchers, Doctors, Pharmaceuticals  and senior scientists. The strength of the Conference is that the participants tend to include all phases of the value chain as well as individuals from a wide variety of sector and countries.

Why to attend???

•  Build your professional network.
•  Hear about the latest research.
•  Improve your presentation and communication skills.
•  Get response on an early version of your latest work.
•  Acquire beyond your field or interest.
•  Get opportunity to people to meet you.
•  Know the strengths and weakness of your conferences.
•  Easier to solve the problems and struggles which you go through at work.

Target Audience:

• Scientists
• Young  research  fellows
• Research Scholars
• Residents, Fellows & Post Docs
• Students
• Business Executives & Directors
• Pulmonologists
• Advertising Agency Executives
• Industry professionals

Market Growth of Green Chemicals:

The global COPD market is estimated to currently be worth $11.3 billion, and is forecast to reach

a value of $15.6 billion by 2019. The drugs driving this growth include once-daily LABA/LAMA

Fixed-dose combinations such as QVA-149, umeclidinium bromide/vilanterol and olodaterol/tiotropium.

The opportunity in the U.S. and China asthma and COPD drugs market is slated to rise from a valuation of US$13.0 bn in 2015 to be worth US$18.7 bn by 2024. If these values hold true, the market is likely to expand at a modest CAGR of 4.1% therein.

North America leads the global market for asthma &COPD drugs and devices. North America was followed by Europe in terms of market capitalization. Asia Pacific is expected to be the fastest regional market for asthma and COPD owing to the increased incidence of asthma & other respiratory diseases in industrial regions.

The current asthma and COPD market is primarily driven by increasing patient population. It is also growing due to factors such as price erosion and expiry of patents of leading drug brands in the market. However, it is estimated that in the next five years, the global asthma and COPD drug market is expected to grow slowly and steadfast. The COPD segment was projected to be worth USD 10,593.2 million and is expected to reach USD 12,619.8 million in 2017.

In Europe, LABA / ICS combinations and LTA (Montelukast) drugs are more popular for asthma and COPD treatment. 

Name:  Jessica Nicole

Contact Number:  44-203-9368-245

Email: copd@asiameets.com

Website:  https://copd.conferenceseries.com/